-
Je něco špatně v tomto záznamu ?
Effects of necrostatin-1, an inhibitor of necroptosis, and its inactive analogue Nec-1i on basal cardiovascular function
A. Szobi, T. Rajtik, A. Adameova,
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- elektrokardiografie MeSH
- imidazoly farmakologie MeSH
- indoly farmakologie MeSH
- krevní tlak účinky léků MeSH
- náhodné rozdělení MeSH
- potkani Wistar MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIP1) by necrostatin-1 (Nec-1) alleviates cardiac injury due to prevention of necroptotic cell death. Its inactive analogue necrostatin-1i (Nec-1i), lacking RIP1 activity, serves as a suitable control. It is unknown if these agents influence the heart function in the absence of damaging stimuli. For this purpose, we measured intraarterial blood pressure (systolic - sBP and diastolic - dBP) and ECG parameters after a bolus administration of Nec-1 and Nec-1i in rats during 30 min. Nec-1, unlike Nec-1i, increased sBP and dBP, as well as heart rate reaching the peak at 20 min. The P wave duration tended to be decreased and the duration of the PR interval was shortened by Nec-1 indicating faster conduction of the impulses through atria to the ventricles. The drugs did not influence the QTc interval duration and no episode of ventricular arrhythmia was observed. In summary, Nec-1 temporarily modulates blood pressure and electrical function of the healthy heart. These effects of Nec-1 are likely due to its off-target action or RIP1 has an important role in the regulation of cardiovascular function independently of its action on the necroptotic pathway.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17012767
- 003
- CZ-PrNML
- 005
- 20170425105017.0
- 007
- ta
- 008
- 170412s2016 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.933393 $2 doi
- 035 __
- $a (PubMed)27875900
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Szobi, Adrian. $u Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovak Republic $7 xx0307133
- 245 10
- $a Effects of necrostatin-1, an inhibitor of necroptosis, and its inactive analogue Nec-1i on basal cardiovascular function / $c A. Szobi, T. Rajtik, A. Adameova,
- 520 9_
- $a Inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIP1) by necrostatin-1 (Nec-1) alleviates cardiac injury due to prevention of necroptotic cell death. Its inactive analogue necrostatin-1i (Nec-1i), lacking RIP1 activity, serves as a suitable control. It is unknown if these agents influence the heart function in the absence of damaging stimuli. For this purpose, we measured intraarterial blood pressure (systolic - sBP and diastolic - dBP) and ECG parameters after a bolus administration of Nec-1 and Nec-1i in rats during 30 min. Nec-1, unlike Nec-1i, increased sBP and dBP, as well as heart rate reaching the peak at 20 min. The P wave duration tended to be decreased and the duration of the PR interval was shortened by Nec-1 indicating faster conduction of the impulses through atria to the ventricles. The drugs did not influence the QTc interval duration and no episode of ventricular arrhythmia was observed. In summary, Nec-1 temporarily modulates blood pressure and electrical function of the healthy heart. These effects of Nec-1 are likely due to its off-target action or RIP1 has an important role in the regulation of cardiovascular function independently of its action on the necroptotic pathway.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a elektrokardiografie $7 D004562
- 650 _2
- $a imidazoly $x farmakologie $7 D007093
- 650 _2
- $a indoly $x farmakologie $7 D007211
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rajtík, Tomáš $7 xx0307132 $u Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovak Republic
- 700 1_
- $a Adameová, Adriana $7 xx0064778 $u Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovak Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 65, č. 5 (2016), s. 861-865
- 856 41
- $u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20170412 $b ABA008
- 991 __
- $a 20170421142035 $b ABA008
- 999 __
- $a ok $b bmc $g 1201945 $s 973540
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 65 $c 5 $d 861-865 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20170412